NCT04579718

Brief Summary

To evaluate the feasibility of Zeus Cloud TPS in the design of photon intensity modulated radiation therapy (IMRT) plan for tumors in various parts of the body.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
63

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Nov 2020

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

September 26, 2020

Completed
12 days until next milestone

First Posted

Study publicly available on registry

October 8, 2020

Completed
24 days until next milestone

Study Start

First participant enrolled

November 1, 2020

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 31, 2022

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

October 31, 2022

Completed
Last Updated

October 8, 2020

Status Verified

October 1, 2020

Enrollment Period

2 years

First QC Date

September 26, 2020

Last Update Submit

October 4, 2020

Conditions

Radiotherapy

Keywords

Treatment Planning System

Outcome Measures

Primary Outcomes (1)

  • The qualification rate of treatment plans based on dosimetry

    2 months

Secondary Outcomes (3)

  • The conformability index of radiation dose to the target

    2 months

  • single-field pass rate

    2 months

  • composite-field pass rate

    2 months

Study Arms (2)

Eclipse

Other: Eclipse

Zeus Cloud TPS V1.0

Other: Zeus Cloud TPS V1.0

Interventions

Zeus Cloud TPS V1.0OTHER

Zeus Cloud TPS V1.0 is used to design the radiotherapy plan for the subjects and the plan is evaluated.

Zeus Cloud TPS V1.0
EclipseOTHER

Eclipse TPS of Varian company is used to design the radiotherapy plan for the subjects and the plan is evaluated.

Eclipse

Eligibility Criteria

Age18 Years - 75 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients with confirmed brain glioma, nasopharyngeal carcinoma, lung cancer, esophageal cancer, gastric cancer, liver cancer, prostate cancer, cervical cancer and rectal cancer.

You may qualify if:

  • Patients with confirmed brain glioma, nasopharyngeal carcinoma, lung cancer, esophageal cancer, gastric cancer, liver cancer, prostate cancer, cervical cancer and rectal cancer;
  • The medical imaging data (CT) of the subjects were complete and available;
  • Between 18 and 75 years old, regardless of gender;

You may not qualify if:

  • The patients had metal implants;
  • Not suitable for clinical trials judged by investigators.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Interventions

Eclipse Prosthodontic Resin

Study Officials

  • Hui Liu, Prof.

    Sun Yat-sen University

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Bo Qiu, MD

CONTACT

+86-020-87343031qiubo@sysucc.org.cn

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

September 26, 2020

First Posted

October 8, 2020

Study Start

November 1, 2020

Primary Completion

October 31, 2022

Study Completion

October 31, 2022

Last Updated

October 8, 2020

Record last verified: 2020-10